Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of Heart Rate Reserve on Exercise Capacity in Patients Treated with a Continuous Left Ventricular Assist Device

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Finn Gustafsson (Medlem af forfattergruppering)
  • REDUCE LAP-HF study investigators
Vis graf over relationer

AIMS: Impaired left ventricular diastolic function leading to elevated left atrial pressures, particularly during exertion, is a key driver of symptoms and outcomes in heart failure with preserved ejection fraction (HFpEF). Insertion of an interatrial shunt device (IASD) to reduce left atrial pressure in HFpEF has been shown to be associated with short-term haemodynamic and symptomatic benefit. We aimed to investigate the potential effects of IASD placement on HFpEF survival and heart failure hospitalization (HFH).

METHODS AND RESULTS: Heart failure with preserved ejection fraction patients participating in the Reduce Elevated Left Atrial Pressure in Patients with Heart Failure study (Corvia Medical) of an IASD were followed for a median duration of 739 days. The theoretical impact of IASD implantation on HFpEF mortality was investigated by comparing the observed survival of the study cohort with the survival predicted from baseline data using the Meta-analysis Global Group in Chronic Heart Failure heart failure risk survival score. Baseline and post-IASD implant parameters associated with HFH were also investigated. Based upon the individual baseline demographic and cardiovascular profile of the study cohort, the Meta-analysis Global Group in Chronic Heart Failure score-predicted mortality was 10.2/100 pt years. The observed mortality rate of the IASD-treated cohort was 3.4/100 pt years, representing a 33% lower rate (P = 0.02). By Kaplan-Meier analysis, the observed survival in IASD patients was greater than predicted (P = 0.014). Baseline parameters were not predictive of future HFH events; however, poorer exercise tolerance and a higher workload-corrected exercise pulmonary capillary wedge pressure at the 6 months post-IASD study were associated with HFH.

CONCLUSIONS: The current study suggests IASD implantation may be associated with a reduction in mortality in HFpEF. Large-scale ongoing randomized studies are required to confirm the potential benefit of this therapy.

OriginalsprogEngelsk
TidsskriftESC Heart Failure
Vol/bind6
Udgave nummer1
Sider (fra-til)62-69
ISSN2055-5822
DOI
StatusUdgivet - 2019

ID: 56234901